IGXT News Alert Intelgenx Technologs (IGXT) 0.5100 09/28/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Intelgenx Technologs (IGXT) 0.5100 $IGXT

IntelGenx to Present at Singular Research 9th Annual Best of the Uncovereds Conference
GlobeNewswire - Wed Sep 17, 8:28AM CDT
IntelGenx Corp. (TSXV:IGX) (OTCQX:IGXT) ("IntelGenx" today announced that Dr. Horst Zerbe, Chairman, President and Chief Executive Officer, will present at the Singular Research 9th Annual Best of the Uncovereds Conference to be held Monday, September 22, 2014 at the Luxe Hotel in Los Angeles, California. IntelGenx' presentation will take place September 22, 2014 at 9:30 AM Pacific Time.

IntelGenx to Present at the Rodman & Renshaw Global Investment Conference
GlobeNewswire - Thu Aug 21, 1:18PM CDT
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" today announced that Dr. Horst Zerbe, Chairman, President and Chief Executive Officer, will present at the Rodman & Renshaw Global Investment Conference to be held September 9, 2014 at 9:35 a.m. Eastern Time.

H.C. Wainwright Initiates Coverage of Pacific Therapeutics Partner Intelgenx with a Buy Recommendation
ACCESSWIRE - Fri Aug 15, 7:48AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / August 15, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company" is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction which are $1 billion plus market opportunities.

IntelGenx Reports Q2, 2014 Results and Provides Corporate Development Update
GlobeNewswire - Thu Aug 07, 8:31AM CDT
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" today announced financial results for the three and six months ended June 30, 2014 and provided an update on corporate developments. All amounts are in U.S. Dollars, unless otherwise stated.

IntelGenx to Host Management Call
GlobeNewswire - Fri Jul 18, 11:38AM CDT
IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" today announced that its interim CEO, Dr. Horst G. Zerbe, will be hosting a conference call on July 23rd, 2014 at 10:00 AM Eastern Time.

IntelGenx Announces Management Changes
GlobeNewswire - Wed Jul 16, 3:52AM CDT
IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" announced today that the board of directors (the "Board" of IntelGenx has accepted, with immediate effect, the resignation of Dr. Rajiv Khosla as President and Chief Executive Officer ("CEO" of IntelGenx and as a member of the Board.

IntelGenx Announces Equity Analyst Coverage by H.C. Wainwright
GlobeNewswire - Tue Jul 01, 7:11AM CDT
IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" today announced that H.C. Wainwright has initiated equity analyst coverage of IntelGenx.

IntelGenx Reports 2013 Annual Results and Provides Corporate Development Update
GlobeNewswire - Tue Mar 11, 7:32AM CDT
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (the "Company" today announced financial results for its fiscal year ended December 31, 2013 and provided an update on operational developments. All amounts are in U.S. Dollars, unless otherwise stated.

IntelGenx and RedHill Biopharma Submit Response to FDA CRL for VersaFilm(TM) Product for Migraines
GlobeNewswire - Mon Mar 03, 7:05AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" , a Canadian drug delivery company focusing on oral drug delivery, today announced, together with RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" , an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage drugs, that they submitted a response to the Complete Response Letter ("CRL" of the U.S. Food and Drug Administration ("FDA" for the New Drug Application ("NDA" for their VersaFilm(TM) Oral Film Product for the treatment of acute migraines.

RedHill Biopharma and IntelGenx Submit Response to FDA CRL for RHB-103 Migraine Oral-Film
GlobeNewswire - Mon Mar 03, 7:00AM CST
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" , an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage drugs, today announced, together with IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" , a Canadian drug delivery company focusing on oral drug delivery, that they submitted a response to the Complete Response Letter ("CRL" of the U.S. Food and Drug Administration ("FDA" for the New Drug Application ("NDA" for RHB-103, an oral thin-film rizatriptan for the treatment of acute migraines.

IntelGenx Announces Receipt of Two Additional U.S. Patent Allowances Related to Proprietary Technology
GlobeNewswire - Wed Feb 26, 7:42AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" , a Canadian drug delivery company focusing on oral drug delivery, today announced that it has received a Notice of Allowance ("NOA" from the United States Patent and Trademark Office for U.S. Patent Application Serial No. 11/647,033 entitled "Multilayer tablet" which covers the technology used in our hypertension product currently under development. A second NOA has been received for U.S. Patent Application Serial No. 11/782,838 entitled "Controlled-release pharmaceutical tablets" which is related to the drug delivery technology used in Forfivo XL(R), IntelGenx' first FDA-approved product currently commercialized in the U.S. These two NOA's conclude the examination of each U.S. patent application and will result in the issuance of two U.S. patents after administrative processes are completed.

IntelGenx Achieves Positive Bioequivalence Results for Erectile Dysfunction VersaFilm(TM) Tadalafil Product
GlobeNewswire - Mon Feb 24, 7:08AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" , a Canadian drug delivery company focusing on oral drug delivery, today announced the completion of a pilot biostudy with its proprietary VersaFilm(TM) tadalafil product for erectile dysfunction that indicated bioequivalence with the leading brand reference listed drug (RLD) tadalafil product.

IntelGenx Technologies Report Delivers Analyst Opinion and Fundamental Data
PR Newswire - Wed Feb 05, 6:00AM CST
NEW YORK, Feb. 5, 2014 /PRNewswire - IntelGenx Technologies Corp (OTC: IGXT), is a drug delivery company, that engages in the development of novel oral immediate-release and controlled-release products for the pharmaceutical market.

IntelGenx and RedHill Biopharma Receive Complete Response Letter From FDA for VersaFilm(TM) Oral Film Product for Acute Migraines
GlobeNewswire - Tue Feb 04, 9:49PM CST
-- FDA's letter accepted the bioequivalence study and safety information submitted and requires no additional clinical studies; IntelGenx and RedHill plan to address remaining issues, primarily related to third party manufacturing, packaging and labeling, within weeks based on available data

11th Trust Dialogue - Impunity Number One Enemy of Democracy-Ekeweremadu
by Ronald Mutum - All Africa Global Media - Fri Jan 17, 1:21AM CST
The Deputy Senate President, Ike Ekeweremadu has said impunity in politics is the number one enemy of Nigeria's democracy.

Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2013
M2 - Tue Sep 10, 3:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4ghj69/idiopathic) has announced the addition of the "Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2013" report to their offering. 'Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Idiopathic Pulmonary Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Idiopathic Pulmonary Fibrosis. Scope - A snapshot of the global therapeutic scenario for Idiopathic Pulmonary Fibrosis. - A review of the Idiopathic Pulmonary Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Idiopathic Pulmonary Fibrosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Boehringer Ingelheim GmbH Sanofi-Aventis GlaxoSmithKline plc MedImmune LLC Gilead Sciences, Inc. FibroGen, Inc. Chong Kun Dang Pharmaceutical InterMune, Inc. IntelGenx Technologies Corp. Compugen Ltd. Pharmaxis Ltd. Hanall Pharmaceutical Co., Ltd. LTT Bio-Pharma Co., Ltd. Auspex Pharmaceuticals Promedior, Inc. Mondobiotech Holding AG GenKyoTex S.A. Stromedix, Inc. ImmuneRegen BioSciences, Inc. ImmuneWorks, LLC Histocell S.L. BiOrion Technologies B.V. Pacific Therapeutics Ltd. For more information visit http://www.researchandmarkets.com/research/4ghj69/idiopathic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Global Insomnia Report - Pipeline Review Analysis
M2 - Wed Sep 04, 10:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gvqfpz/insomnia) has announced the addition of the "Insomnia - Pipeline Review, H2 2013" report to their offering. 'Insomnia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Insomnia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Insomnia. Scope - A snapshot of the global therapeutic scenario for Insomnia. - A review of the Insomnia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Insomnia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Insomnia Therapeutics Development - Merck & Co., Inc. - Actelion Ltd - Eisai Co., Ltd. - Mitsubishi Tanabe Pharma Corporation - Evotec Aktiengesellschaft - IntelGenx Technologies Corp. - Neurim Pharmaceuticals Ltd. - Intas Pharmaceuticals Ltd. - Angelini Group - Abeille Pharmaceuticals, Inc. - Intec Pharma ltd. - Ferrer Internacional S.A. - Somnus Therapeutics, Inc. - Intra-Cellular Therapies, Inc. - Kuhnil Pharmaceutical Co., Ltd. - Heptares Therapeutics Ltd. Drug Profiles - suvorexant - suvorexant - Piromelatine - AB-1003 - osemozotan - zaleplon DR - EVT-201 - Orexin-2 - ITI-007 - CR-5542 Series - melatonin - filorexant - zaleplon - INAQUL-001 - eszopiclone - Drug Targeting Orexin 1/2 - E-2006 - trazodone hydrochloride - UCM-765 - Orexin Receptor Antagonist - lorediplon - KI-1001 - Orexin-1 Antagonist - Dual Orexin Receptor Antagonists For more information visit http://www.researchandmarkets.com/research/gvqfpz/insomnia

Migraine - Pipeline Review, H2 2013
M2 - Wed Sep 04, 9:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/47gndq/migraine) has announced the addition of the "Migraine - Pipeline Review, H2 2013" report to their offering. 'Migraine - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Migraine, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Migraine. Scope - A snapshot of the global therapeutic scenario for Migraine. - A review of the Migraine products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Migraine pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Allergan, Inc. Amgen Inc. Questcor Pharmaceuticals, Inc. BioDelivery Sciences International, Inc. Merck & Co., Inc. Biofrontera AG Dr. Reddy's Laboratories Limited Teva Pharmaceutical Industries Limited Zosano Pharma, Inc. Capnia, Inc. Revance Therapeutics, Inc. IntelGenx Technologies Corp. NovaDel Pharma, Inc. Paladin Labs Inc. POZEN Inc. Choongwae Pharma Corp Orexo AB D-Pharm Ltd. Ache Laboratorios Farmaceuticos S/A Alder Biopharmaceuticals Inc. CoLucid Pharmaceuticals, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/47gndq/migraine About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

XKIG Bolsters Northwest with Jensen's Acquisition

Updated Category News Views 13

Stepping Up the Game in the Pacific Northwest Well, here we see another classic example of a shrewd move in the infrastructure sector. XKIG, a name known to those who keep an eye on critical infrastructure services for utilities, has decided to widen its footprint with a strategic grab of Jensen's Tree Service, Inc. They’re setting up shop even deeper in the Pacific...

Continue Reading
Sue Egstrand to Lead Karo's Next Growth Phase

Updated Category News Views 152

A New Captain at Karo’s Helm Karo Healthcare is bracing for an exciting ride. Sue Egstrand’s appointment as the new CEO pulls the curtain on what might just be a game-changing era for the company. Set to take the wheel on January 1, 2027, Egstrand brings a heavy-hitting resume—a mash-up of pharmaceutical prowess and a deep-dive into consumer healthcare. Sue’s...

Continue Reading
ISC2 Launches AI Security Academy for Cyber Pros

Updated Category News Views 77

AI-Driven Threats Demand Expert Attention Every corner of the tech world has been blabbering about AI, but when it comes to cybersecurity, it's a whole different beast entirely. ISC2—a nonprofit that I like to think of as the cyber wizards’ guild—just threw a lifeline to cybersecurity folks who are swimming in the deep end of AI. With their shiny new AI Security...

Continue Reading
Phoenix Contact Achieves Guinness Record in Wiring

Updated Category News Views 160

A Blitz of Wires and Innovation Boy, did Phoenix Contact shake things up in Blomberg. On a crisp November day, a group of fresh-faced first-year students pulled off something astounding—wiring 500 terminal blocks in a jaw-dropping 2 minutes and 20 seconds. This wasn’t just any effort; it was enough to earn them a shiny new Guinness World Record. What they did wasn’t...

Continue Reading
ICEYE Launches Gen5 SAR Satellite for Unrivaled Clarity

Updated Category News Views 92

Well, if you've been sleeping under a rock and missed the news, ICEYE just dropped another bombshell in the satellite biz. Gen5 is the name of the game, and it's claiming the spotlight for its razor-sharp imaging prowess. Now, we're talking about a satellite that supposedly snaps pictures with a resolution as fine as 11 cm. That's like spotting a flea on a dog's back from...

Continue Reading
NaLA Pushes for Stronger Lifeline Fraud Measures

Updated Category News Views 31

Here's the thing about the Lifeline program: it's meant to be a lifeline, not a loophole for the crafty and unscrupulous. The National Lifeline Association (NaLA) is slamming the table, demanding that the Senate Commerce Committee put some real muscle into preventing fraud. Why the Urgency on Lifeline Fraud? NaLA’s got its sights on a more robust defensive line against...

Continue Reading
Surgical Tooth Extraction: When It’s Necessary

Updated Category News Views 42

Unpacking the Complexities of Tooth Extraction Ever wonder why some tooth extractions are a stroll in the park while others dive straight into surgical territory? It's all about positioning, condition, and what's lurking underneath. Thanks to Dr. Yadira Cardona-Rohena of Hamilton Mill Oral & Facial Surgery, we’ve got the lowdown. The Need for Skilled Surgical Techniques...

Continue Reading
Visit W&H at the Greater New York Dental Meeting

Updated Category News Views 52

Why This Event Matters for Dental Professionals Stroll through any convention center halls and you can see the future unfolding right in front of you. The upcoming Greater New York Dental Meeting is no different, especially with W&H Group setting up shop. For any dental professionals out there, this is your chance to get your hands on some real-deal tech that might just...

Continue Reading
DarioHealth's New Research Tackles Healthcare Cost Estimation

Updated Category News Views 104

Unpacking Dario's Bold Surgical Strike at ISPOR Europe Alright, folks, DarioHealth is shaking up the stage with their new methodology that could very well carve a new path in how we size up digital healthcare savings. Presented at ISPOR Europe 2026, Dario's tactic bypasses the sluggish wait on medical claims data, instead offering an evidence-driven peek at potential...

Continue Reading
Alley Cat Allies Pushes for Humane Cat Conservation Bill

Updated Category News Views 22

Time to Rethink Conservation: Save the Cats If you’re tuned into the chatter buzzing around the Cayman Islands, you know the clocks are ticking for a decision that could change the approach to handling community cats. Alley Cat Allies is waving the flag, urging the Cayman Islands Parliament to pass a bill that abandons the archaic practice of culling cats by shooting...

Continue Reading

Top 5 Most Recently Viewed Articles

Ethan Allen Launches Stylish Design Center in Colorado Springs

Updated Category News Views 229

Introducing the New Ethan Allen Design Center Ethan Allen has proudly opened its latest Design Center in Colorado Springs, situated in the vibrant University Village Shopping Center. This newly constructed space features a beautiful gallery showroom, along with workspaces designed for collaboration between designers and clients. This new center is the fourth for Ethan...

Continue Reading
Understanding Ark Invest's Strategic Moves with AI Leaders

Updated Category News Views 349

Ark Invest's Bold Moves in the AI Sector Cathie Wood, the impactful leader of Ark Invest, continues to make headlines with her investment decisions. Recently, Ark made some noteworthy trades involving Baidu Inc. (NASDAQ: BIDU), Alibaba Group Holding Ltd. (NYSE: BABA), and Brera Holdings PLC (NASDAQ: BREA). These investments spotlight Ark's belief in companies championing...

Continue Reading
Broadcom's Future: Analyst Ratings Fuel Optimism for 2026

Updated Category News Views 287

Broadcom's Impressive Rally and Analysts' Confidence Recently, semiconductor giant Broadcom saw a remarkable rebound, achieving a staggering total return of 51%. This performance stands in sharp contrast to the previous year's underwhelming conclusion. Investors have taken a keen interest in the company, especially as it consistently outpaces the S&P 500’s return, which...

Continue Reading
Novavax's Earnings Preview: What Investors Should Expect

Updated Category News Views 160

Key Insights Before Novavax's Earnings Report Novavax (NASDAQ: NVAX) is set to announce its quarterly earnings soon, and anticipation is building among investors. This overview highlights essential factors for those interested in the upcoming earnings report. Expected Earnings Performance Analysts predict that Novavax will report an earnings per share (EPS) of...

Continue Reading
Bank7 Corp. Reports Impressive Q3 2024 Earnings Results

Updated Category News Views 130

Bank7 Corp. Achieves Record Earnings for Q3 2024 Bank7 Corp. (NASDAQ: BSVN), the parent company of Bank7, has announced outstanding financial results for the third quarter of 2024. In a recent statement, President and CEO Thomas L. Travis remarked, "We are pleased to announce another record quarter of net income and EPS. Our properly matched balance sheet, disciplined...

Continue Reading